Dan Shores is a partner at Rothwell Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets and leads teams in building patent portfolios, negotiating strategic collaborations, conducting due diligence and landscape investigations and litigating complex patent disputes. Dan has served companies utilizing the following technologies (without limitation): mRNA; lipid nanoparticles; CAR-T therapies; CRISPR; oligonucleotides; genetically engineered swine organs for xenotransplantation; artificial intelligence for drug discovery; pharmaceutical treatment of rhinitis with levocetirizine; pharmaceutical treatment of hepatitis B with telbivudine; and numerous other technologies throughout his 18-year career. Dan holds a B.S. with a materials science specialization from the University of New Hampshire and a J.D. from the Georgetown University Law Center where he served on the Editorial Board of the Georgetown Law Review. He is a registered patent attorney licensed to practice before the United States Patent and Trademark Office and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan is an active member of the Intellectual Property Owners Association Pharmaceutical and Biotechnology Issues Committee.
